Sarah Boyce, Avidity Biosciences CEO
August 9, 2024 10:52 AM EDT
R&D

Avid­i­ty CEO says it's ‘full steam ahead’ in DMD as stock ral­lies on Phase 1/2 win

Andrew Dunn

Senior Biopharma Correspondent

The Duchenne mus­cu­lar dy­s­tro­phy com­mu­ni­ty re­ceived some rare good news on Fri­day when Avid­i­ty Bio­sciences re­port­ed sur­pris­ing­ly pos­i­tive clin­i­cal re­sults in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times